Ferumoxytol MRA for transcatheter aortic valve replacement planning with renal insufficiency. (15th March 2017)

• Record Type: Journal Article
• Authors: Kallianos, Kimberly; Henry, Travis S.; Yeghiazarians, Yerem; Zimmet, Jeffrey; Shunk, Kendrick A.; Tseng, Elaine E.; Mahadevan, Vaikom; Hope, Michael D.
• Is Part Of: International journal of cardiology. Volume 231(2017)
• Page Start: 255
• Page End: 257
• Publication Date: 2017-03-15
• Subjects: Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2016.12.147
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: Computed tomography angiography (CTA) is the test of choice for pre-procedure imaging of transcatheter aortic valve replacement (TAVR) candidates. The iodinated contrast required, however, increases the risk of renal dysfunction in patients with pre-existing renal failure. Ferumoxytol is a magnetic resonance imaging (MRI) contrast agent that can be used with renal failure. Its long vascular resonance time allows gated MRA sequences that approach CTA in image quality. We present respiratory and cardiac gated MRA enabled by ferumoxytol that can be post-processed in an analogous fashion to CTA. Methods: Seven patients with renal failure presenting for TAVR were imaged with respiratory and cardiac gated MRA at 3T using ferumoxtyol for contrast. Aortic annulus, root and peripheral access dimensions were calculated in a fashion identical to that used for CTA. Of these, 6 patients underwent a TAVR procedure and 5 had intraoperative valve assessment with transesophageal echocardiograph (TEE) using standard clinical protocols that employed both two- and three-dimensional techniques. Results: Good correlation between MRA aortic annulus measurements and those from TEE were shown in 5 patients with mean annulus area of 392.4 mm 2 (290–470 range) versus 374.1 mm 2 (285–440 range), with a pairwise correlation coefficient of 0.92, p = 0.029. All patients received Sapien valve implants (one 20 mm, three 23 mm, and two 26 mm valves). Access decisions were guided by MRA with no complications. Annulus sizing resulted in no greater than trace/mild aortic regurgitation in all patients. Conclusions: Ferumoxytol MRA is a safe alternative to CTA in patients with renal failure for pre-TAVR analysis of the aortic root and peripheral access.